In the past fifteen years, HairGenesis® has gone through four significant formulation improvements.  In 1995, 

HairGenesis® began as an idea to use natural substances in the clinical treatment of pattern hair loss.  Arising from

a need to stop the progression of hair loss in patients undergoing surgical hair restoration, the first generation of

HairGenesis® achieved excellent results, particularly given the relative simplicity of the early formula.  

Today, Generation IV HairGenesis® represents the state of the art in naturally derived hair loss treatment 

methodology.  Combining potent inhibitors of the pathologic enzyme 5 alpha reductase with novel anti-inflammatory

reagents, the latest version of HairGenesis® represents a genuine step forward in the treatment of pattern hair loss.

One of the most important features associated with the new formula is its dual-mechanism

design and deployment.  Pattern hair loss is known in the vernacular as a complex trait disorder.  This means that

multiple factors including genetics, environment and biochemistry contribute to the onset and progression of the disease.

Until very recently, essentially the entire treatment field focused on blocking various facets of dihdrotestosterone metablism,

i.e. by placing impediments in the path of 5 alpha reductase, the enzyme precursor that converts testosterone to its more

virulent metabolite, DHT.  While a sensible beginning, this approach is self-limiting due to the fact that other important

factors undoubtedly are relevant in the disease.  Among the more obvious candidates is inflammation.  

In the past few years, inflammation has become one of the most important disease causing targets for research scientists 

working across far ranging fields.  These fields include cancer research, diseases of the skeletal system, aging, etc.  Inflammation

constitutes a unifying theme in the breakdown of systemic homeostasis wherein errors of gene transcription and downstream 

biochemistry result in the onset and progression of many disorders.  

In our lab, and over the course of the past two years in particular, a key hypothesis has been that certain aspects of inflammation are an under-appreciated co-factor in common pattern hair loss.  Working with collaborators at the University of Albany and elsewhere, this hypothesis has borne fruit.  Generation IV HairGenesis® constitutes a tangible touchstone for this work.  

More to come....